Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LIMITED SPON ADR EACH REP 300 ORD

4.23
-0.4300-9.23%
Post-market: 4.550.3200+7.57%18:02 EST
Volume:43.67K
Turnover:180.85K
Market Cap:33.35M
PE:-1.17
High:4.60
Open:4.60
Low:4.05
Close:4.66
52wk High:50.82
52wk Low:3.50
Shares:7.88M
Float Shares:5.05M
Volume Ratio:3.14
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6237
EPS(LYR):-3.6237
ROE:-109.20%
ROA:-27.70%
PB:1.13
PE(LYR):-1.17

Loading ...

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:06 PM

Reuters
·
Nov 21

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

GlobeNewswire
·
Nov 18

Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases

GlobeNewswire
·
Nov 17

Radiopharm starts enrollment of third cohort in Phase 1 trial of 177Lu-RAD204

TIPRANKS
·
Nov 12

Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204

GlobeNewswire
·
Nov 12

Analysts’ Top Healthcare Picks: Tango Therapeutics (TNGX), Radiopharm Theranostics Limited Sponsored ADR (RADX)

TIPRANKS
·
Oct 27

Radiopharm Theranostics Expects to Raise $22.7 Million Via Private Placement, Shares Down Pre-Bell

MT Newswires Live
·
Oct 20

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

GlobeNewswire
·
Oct 20

Radiopharm launches A$5M share purchase plan

TIPRANKS
·
Oct 20

Radiopharm Theranostics trading resumes

TIPRANKS
·
Oct 14

Radiopharm receives DSMC recommendation to advance Phase 1 ‘HEAT’ trial

TIPRANKS
·
Oct 01

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEAT’ Dose Escalation Clinical Trial

GlobeNewswire
·
Oct 01

Radiopharm Theranostics trading halted, volatility trading pause

TIPRANKS
·
Sep 11

Radiopharm Theranostics Reported FY25 Cash Balance Of $29.12M, Operating Cash Flow Of $36.67M, Confirmed Guidance of Cash Runway Through To Mid-2026

Benzinga
·
Jul 29

Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update

GlobeNewswire
·
Jul 29

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

GlobeNewswire
·
Jul 28

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

GlobeNewswire
·
Jul 22